Opsens Inc
TSX:OPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Opsens Inc
TSX:OPS
|
CA |
|
Umicore SA
XBRU:UMI
|
BE |
|
Brain Scientific Inc
OTC:BRSF
|
US |
|
Sok Marketler Ticaret AS
IST:SOKM.E
|
TR |
|
W
|
Whirlpool SA
BOVESPA:WHRL3
|
BR |
|
Stantec Inc
TSX:STN
|
CA |
|
GOME Retail Holdings Ltd
HKEX:493
|
CN |
Opsens Inc
Opsens, Inc. engages in the development, manufacture, supply, and installation of fiber optic systems for measuring pressure and temperature. The firm operates through two segments: Medical and Industrial. The Medical segment focuses on physiological measurement, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that is integrated in other medical devices. The company also includes optical sensor technology. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for industrial applications. The firm also offers an optical-based pressure guidewire (OptoWire) that is focused on improving the clinical outcome of patients with coronary artery disease.
Opsens, Inc. engages in the development, manufacture, supply, and installation of fiber optic systems for measuring pressure and temperature. The firm operates through two segments: Medical and Industrial. The Medical segment focuses on physiological measurement, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that is integrated in other medical devices. The company also includes optical sensor technology. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for industrial applications. The firm also offers an optical-based pressure guidewire (OptoWire) that is focused on improving the clinical outcome of patients with coronary artery disease.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
